Clinical Characteristics of Nephrotic Syndrome Associated with Malignancy.
- Author:
Jung Tak PARK
1
;
Joo Seong KIM
;
Hyung Jong KIM
;
Dong Ryeol RYU
;
Tae Hyun YOO
;
Hoon Young CHOI
;
Jung Eun LEE
;
Taeik CHANG
;
Seung Chul LEE
;
Hyeon Joo JEONG
;
Kyu Hun CHOI
;
Ho Yung LEE
;
Dae Suk HAN
;
Shin Wook KANG
Author Information
1. Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Korea. kswkidney@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Malignancy;
Nephrotic syndrome;
Renal biopsy
- MeSH:
Adenocarcinoma;
Adult;
Biopsy;
Glomerulonephritis, IGA;
Glomerulonephritis, Membranoproliferative;
Glomerulonephritis, Membranous;
Humans;
Korea;
Liver;
Lung;
Medical Records;
Nephrosis, Lipoid;
Nephrotic Syndrome*;
Pathology;
Retrospective Studies;
Sex Ratio
- From:Korean Journal of Nephrology
2004;23(5):738-745
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Even though there have been many case reports on nephrotic syndrome in patients with malignancy, an overall study on malignancy- associated nephrotic syndrome is rare in Korea. The purpose of this study was to explore the clinical and pathologic findings and clinical course of malignancy-associated nephrotic syndrome. METHODS: From January, 1986 to December, 2003, the medical records of patients with nephrotic syndrome and concomitant malignancy were retrospectively reviewed. RESULTS: Forty-eight patients (2.3%) out of 2, 085 patients with nephrotic syndrome had concomitant malignant disease during the study period. The mean age of patients was 57.9+-1.6 years with sex ratio of 2.4: 1. The most common primary origin of malignancy was liver (8 patients, 16.7%) and lungs (8 patients, 16.7%), and adenocarcinoma (17 patients, 35.4 %) was the leading histologic type of malignancy. There was no significant difference in 24-hour urinary protein excretion among patients grouped by TNM stage. Percutaneous renal biopsy was performed in 26 patients (54.2%), renal pathology revealed membranous nephropathy and minimal change disease in 9 patients (34.6%) each, membranoproliferative glomerulonephritis in 6 (23.1%), and IgA nephropathy in 2 patients (7.7%). When the patients were divided into progression and remission group based on the clinical course of underlying malignancy, there were significantly more patients with improved nephrotic syndrome in the remission group than the progression group (55.0% vs. 0%, p<0.05). CONCLUSION: Malignancy should be considered as a cause of nephrotic syndrome in adults, and the treatment of underlying malignancy may affect the outcome of nephrotic syndrome in patients with malignancy.
